MAOIs and depression treatment guidelines.
Monoamine oxidase inhibitors (MAOIs) have proven efficacy for treating depression, particularly in patients with atypical depression, high levels of anxiety, anergic bipolar depression, and treatment-resistant depression. However, MAOIs are not supported as first-line treatments due to safety and tolerability concerns and the need for dietary restrictions; instead, current guidelines recommend MAOIs as third-, fourth-, or fifth-line treatments. However, a newer, transdermal MAOI formulation limits the need for dietary restrictions and has fewer sexual and metabolic effects than some of the newer antidepressants.
From the Departments of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia Veterans Affairs Medical Center, and the University of Pittsburgh Medical Center, Philadelphia and Pittsburgh.
Michael E
ME
Thase
D000279:Administration, Cutaneous; D000928:Antidepressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003863:Depression / Q000188:drug therapy*; D006801:Humans; D008996:Monoamine Oxidase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic
D000928:Antidepressive Agents; D008996:Monoamine Oxidase Inhibitors